[
  {
    "ts": "2025-09-04T20:01:00+00:00",
    "headline": "AMGEN TO PRESENT AT THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE",
    "summary": "Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 9:15 a.m. ET on September 9, 2025. Peter Griffith, executive vice president and chief financial officer at Amgen, and Kave Niksefat, senior vice president of Global Marketing and Access at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.",
    "url": "https://finance.yahoo.com/news/amgen-present-morgan-stanley-23rd-200100350.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "d74afc02-2fd6-3722-b313-9418e5ea0e74",
      "content": {
        "id": "d74afc02-2fd6-3722-b313-9418e5ea0e74",
        "contentType": "STORY",
        "title": "AMGEN TO PRESENT AT THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE",
        "description": "",
        "summary": "Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 9:15 a.m. ET on September 9, 2025. Peter Griffith, executive vice president and chief financial officer at Amgen, and Kave Niksefat, senior vice president of Global Marketing and Access at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.",
        "pubDate": "2025-09-04T20:01:00Z",
        "displayTime": "2025-09-04T20:01:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/dd88fc63427022d71ca8183432abc09d",
          "originalWidth": 400,
          "originalHeight": 98,
          "caption": "Amgen Logo. (PRNewsFoto/Amgen) (PRNewsFoto/)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9xF64eSNrBTdXVSUBRIisA--~B/aD05ODt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/dd88fc63427022d71ca8183432abc09d.cf.webp",
              "width": 400,
              "height": 98,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LmrL8PQB2Q2cD.YsureBSw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/dd88fc63427022d71ca8183432abc09d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/amgen-present-morgan-stanley-23rd-200100350.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amgen-present-morgan-stanley-23rd-200100350.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-04T18:54:00+00:00",
    "headline": "Nvidia Invests in Honeywell’s Quantinuum. What It Means for D-Wave, IonQ, and Quantum Stocks.",
    "summary": "Quantinuum and Nvidia have a ‘shared vision’ for quantum computing, CEO Rajeeb Hazra previously told Barron’s.",
    "url": "https://www.barrons.com/articles/nvidia-honeywell-quantinuum-quantum-stocks-c59dc297?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "66151c1e-99a5-333f-8270-59bc36350033",
      "content": {
        "id": "66151c1e-99a5-333f-8270-59bc36350033",
        "contentType": "STORY",
        "title": "Nvidia Invests in Honeywell’s Quantinuum. What It Means for D-Wave, IonQ, and Quantum Stocks.",
        "description": "",
        "summary": "Quantinuum and Nvidia have a ‘shared vision’ for quantum computing, CEO Rajeeb Hazra previously told Barron’s.",
        "pubDate": "2025-09-04T18:54:00Z",
        "displayTime": "2025-09-04T18:54:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/66151c1e-99a5-333f-8270-59bc36350033/nvidia-invests-in-honeywell%E2%80%99s.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/33c53643bc2c56ba85a5c0893f3c6280",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3RhnLMMtnHRPO5Jsa9eCTQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/33c53643bc2c56ba85a5c0893f3c6280.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KosTVGN.3jpSBJ2RVyy1Fg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/33c53643bc2c56ba85a5c0893f3c6280.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/nvidia-honeywell-quantinuum-quantum-stocks-c59dc297?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IONQ-WS"
            },
            {
              "symbol": "RGTIW"
            },
            {
              "symbol": "QBTS-WS"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "QBTS"
            },
            {
              "symbol": "HON"
            },
            {
              "symbol": "IONQ"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "RGTI"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-04T18:46:11+00:00",
    "headline": "Biotech company Amgen set to build $600-million research center in Thousand Oaks",
    "summary": "Biotech company invests in its roots in Thousand Oaks. On Tuesday, the business announced the building of a 'state-of-the-art' research center, which will cost around $600 million.",
    "url": "https://finance.yahoo.com/news/biotech-company-amgen-set-build-184611246.html",
    "source": "LA Times",
    "provider": "yfinance",
    "raw": {
      "id": "3998ed34-970f-3d4c-9bae-d3682b14ff21",
      "content": {
        "id": "3998ed34-970f-3d4c-9bae-d3682b14ff21",
        "contentType": "STORY",
        "title": "Biotech company Amgen set to build $600-million research center in Thousand Oaks",
        "description": "",
        "summary": "Biotech company invests in its roots in Thousand Oaks. On Tuesday, the business announced the building of a 'state-of-the-art' research center, which will cost around $600 million.",
        "pubDate": "2025-09-04T18:46:11Z",
        "displayTime": "2025-09-04T18:46:11Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/la_times_articles_853/cc8edcbaf7b520783b3d48e5cae325d8",
          "originalWidth": 840,
          "originalHeight": 560,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lFyvHiGckhpnzrTutIA_rA--~B/aD01NjA7dz04NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/la_times_articles_853/cc8edcbaf7b520783b3d48e5cae325d8.cf.webp",
              "width": 840,
              "height": 560,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tklzzd39FAOWY1.5Qxg1bw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/la_times_articles_853/cc8edcbaf7b520783b3d48e5cae325d8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "LA Times",
          "url": "https://www.latimes.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biotech-company-amgen-set-build-184611246.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biotech-company-amgen-set-build-184611246.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-04T18:36:14+00:00",
    "headline": "Why Is Sanofi Stock Falling Thursday?",
    "summary": "On Thursday, Sanofi SA (NASDAQ:SNY) stock tumbled after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fresh doubts about the company’s ability to sustain its dermatology franchise once patent protections expire. Results from the global COAST 1 phase 3 study showed that amlitelimab met all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful ski",
    "url": "https://finance.yahoo.com/news/why-sanofi-stock-falling-thursday-183614792.html",
    "source": "Benzinga",
    "provider": "yfinance",
    "raw": {
      "id": "cbf9d33a-486e-34dc-a32b-9193b0eeb79b",
      "content": {
        "id": "cbf9d33a-486e-34dc-a32b-9193b0eeb79b",
        "contentType": "STORY",
        "title": "Why Is Sanofi Stock Falling Thursday?",
        "description": "",
        "summary": "On Thursday, Sanofi SA (NASDAQ:SNY) stock tumbled after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fresh doubts about the company’s ability to sustain its dermatology franchise once patent protections expire. Results from the global COAST 1 phase 3 study showed that amlitelimab met all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful ski",
        "pubDate": "2025-09-04T18:36:14Z",
        "displayTime": "2025-09-04T18:36:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Benzinga/d99665952a74e6130e0b22cafcb6e712",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "Why Is Sanofi Stock Falling Thursday?",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IJc49uacEMsUszBrlLZ_6g--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/d99665952a74e6130e0b22cafcb6e712.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bYZ.lUqMxCvyair8GUtOKQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/d99665952a74e6130e0b22cafcb6e712.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Benzinga",
          "url": "http://www.benzinga.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-sanofi-stock-falling-thursday-183614792.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-sanofi-stock-falling-thursday-183614792.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SNY"
            },
            {
              "symbol": "SNYNF"
            },
            {
              "symbol": "SAN.PA"
            },
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-04T17:32:35+00:00",
    "headline": "Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Value investing subreddit by Significant-Foot3928. In this article, we will summarize the bulls’ thesis on REGN. Regeneron Pharmaceuticals, Inc.’s share was trading at $589.48 as of August 22nd. REGN’s trailing and forward P/E were 14.86 and 16.18 respectively according to Yahoo Finance. Regeneron Pharmaceuticals operates as […]",
    "url": "https://finance.yahoo.com/news/regeneron-pharmaceuticals-inc-regn-bull-173235172.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "d0bcb935-e635-3446-a2a3-9db3589133d1",
      "content": {
        "id": "d0bcb935-e635-3446-a2a3-9db3589133d1",
        "contentType": "STORY",
        "title": "Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory",
        "description": "",
        "summary": "We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Value investing subreddit by Significant-Foot3928. In this article, we will summarize the bulls’ thesis on REGN. Regeneron Pharmaceuticals, Inc.’s share was trading at $589.48 as of August 22nd. REGN’s trailing and forward P/E were 14.86 and 16.18 respectively according to Yahoo Finance. Regeneron Pharmaceuticals operates as […]",
        "pubDate": "2025-09-04T17:32:35Z",
        "displayTime": "2025-09-04T17:32:35Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/05091c2b4af540bdca13bdc30e634918",
          "originalWidth": 1000,
          "originalHeight": 734,
          "caption": "10 Pharmacist Shortage Countries in Need of Pharmacists in 2017",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5Cgq4qWQpqkPoq.QRSiG3g--~B/aD03MzQ7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/05091c2b4af540bdca13bdc30e634918.cf.webp",
              "width": 1000,
              "height": 734,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/j4x0D9A.Sa_MLOotI128Ng--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/05091c2b4af540bdca13bdc30e634918.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-pharmaceuticals-inc-regn-bull-173235172.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-pharmaceuticals-inc-regn-bull-173235172.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            },
            {
              "symbol": "SAN.PA"
            },
            {
              "symbol": "ROG.SW"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-04T13:25:27+00:00",
    "headline": "Nvidia Investment In Honeywell's Quantinuum Sends Quantum Computing Stocks Up",
    "summary": "Quantum computing stocks climbed after Honeywell-controlled Quantinuum announced a new funding round, with Nvidia among new investors.",
    "url": "https://www.investors.com/news/technology/nvidia-investment-honeywell-quantinuum-sends-quantum-computing-stocks-up/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "efe83afc-a993-3159-b9ed-d9e14cbab546",
      "content": {
        "id": "efe83afc-a993-3159-b9ed-d9e14cbab546",
        "contentType": "STORY",
        "title": "Nvidia Investment In Honeywell's Quantinuum Sends Quantum Computing Stocks Up",
        "description": "",
        "summary": "Quantum computing stocks climbed after Honeywell-controlled Quantinuum announced a new funding round, with Nvidia among new investors.",
        "pubDate": "2025-09-04T13:25:27Z",
        "displayTime": "2025-09-04T13:25:27Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/efe83afc-a993-3159-b9ed-d9e14cbab546/nvidia-investment-in.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/22b49d1430ad4c678d6e6e97f1671791",
          "originalWidth": 1000,
          "originalHeight": 511,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cquDerD_RJ44ZfuDmlNH0Q--~B/aD01MTE7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/22b49d1430ad4c678d6e6e97f1671791.cf.webp",
              "width": 1000,
              "height": 511,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BjNGLyu0eScIUzHjD9XoRg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/22b49d1430ad4c678d6e6e97f1671791.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/nvidia-investment-honeywell-quantinuum-sends-quantum-computing-stocks-up/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RGTI"
            },
            {
              "symbol": "RGTIW"
            },
            {
              "symbol": "IONQ"
            },
            {
              "symbol": "IONQ-WS"
            },
            {
              "symbol": "QBTS"
            },
            {
              "symbol": "QBTS-WS"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "HON"
            },
            {
              "symbol": "2382.TW"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "8031.T"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-04T13:00:00+00:00",
    "headline": "FUJIFILM Biotechnologies Welcomes Samuel Hernandez as Site Head of Texas Facility",
    "summary": "COLLEGE STATION, Texas, September 04, 2025--FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization for biologics, vaccines, and advanced therapies, is pleased to announce the appointment of Samuel Hernandez, Ph.D., as senior vice president and site head for its College Station, Texas facility, effective Monday, August 25. With over two decades of biotechnology and pharmaceutical leadership experience, Dr. Hernandez is poised to lead the Texas site’s approxi",
    "url": "https://finance.yahoo.com/news/fujifilm-biotechnologies-welcomes-samuel-hernandez-130000825.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "b459de6c-7536-36ab-9c46-dc5ce93df266",
      "content": {
        "id": "b459de6c-7536-36ab-9c46-dc5ce93df266",
        "contentType": "STORY",
        "title": "FUJIFILM Biotechnologies Welcomes Samuel Hernandez as Site Head of Texas Facility",
        "description": "",
        "summary": "COLLEGE STATION, Texas, September 04, 2025--FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization for biologics, vaccines, and advanced therapies, is pleased to announce the appointment of Samuel Hernandez, Ph.D., as senior vice president and site head for its College Station, Texas facility, effective Monday, August 25. With over two decades of biotechnology and pharmaceutical leadership experience, Dr. Hernandez is poised to lead the Texas site’s approxi",
        "pubDate": "2025-09-04T13:00:00Z",
        "displayTime": "2025-09-04T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/fujifilm-biotechnologies-welcomes-samuel-hernandez-130000825.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fujifilm-biotechnologies-welcomes-samuel-hernandez-130000825.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]